ReviewAnnals of medicine and surgery (2012)2025
Pulsed field ablation for pulmonary vein and left atrial posterior wall isolation in persistent atrial fibrillation: a narrative review.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulsed-field ablation (PFA) is an emerging technique for managing atrial fibrillation (AF). Still, its role in persistent AF (PeAF) with left atrial posterior wall isolation (LAPWI) remains to be defined. The ATHENA registry evaluated 249 PeAF patients across 9 Italian centers using the FARAPULSE PFA system, with 57.6% undergoing LAPWI. Electrical isolation of the posterior wall was achieved in all cases, with a first-pass success rate of 88.8%. The procedure demonstrated a favorable safety profile, with no major periprocedural complications and only a low rate of minor events (2.4%). Secondary endpoints further assessed long-term efficacy and safety, with 16.5% of patients experiencing arrhythmic recurrence beyond the blanking period at a median follow-up of 273 days, corresponding to an overall freedom from recurrence of 83.5%. Complication rates remained low throughout follow-up, with no late-occurring major adverse events reported. Redo procedures were required in 15.3% of LAPWI patients compared with lower rates in the PVI-only group, suggesting a potential benefit of adjunctive posterior wall ablation. These findings support PFA as a feasible, safe, and efficient approach for LAPWI in PeAF, even with fluoroscopy-only guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.